好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Press Release

EMBARGOED FOR RELEASE UNTIL 4 PM ET, August 09, 2023

Long-Term Use of Certain Acid Reflux Drugs Linked to Higher Risk of Dementia

MINNEAPOLIS 鈥 People who take acid reflux medications called proton pump inhibitors for four-and-a-half years or more may have a higher risk of dementia compared to people who do not take these medications, according to new research published in the August 9, 2023, online issue of , the medical journal of the 好色先生. The study only looked at prescription medications. Over-the-counter medications were excluded. This study does not prove that acid reflux drugs cause dementia; it only shows an association. Acid reflux is when stomach acid flows into the esophagus, usually after a meal or when lying down. People with acid reflux may experience heartburn and ulcers. People with frequent acid reflux may develop gastroesophageal reflux disease, or GERD, which can lead to cancer of the esophagus. Proton pump inhibitors reduce stomach acid by targeting the enzymes in the stomach lining that produce that acid. 鈥淧roton pump inhibitors are a useful tool to help control acid reflux, however long-term use has been linked in previous studies to a higher risk of stroke, bone fractures and chronic kidney disease,鈥 said study author Kamakshi Lakshminarayan, MBBS, PhD, of the University of Minnesota School of Public Health in Minneapolis, and a member of the 好色先生. 鈥淪till, some people take these drugs regularly, so we examined if they are linked to a higher risk of dementia. While we did not find a link with short-term use, we did find a higher risk of dementia associated with long-term use of these drugs.鈥 The study included 5,712 people, age 45 and older, who did not have dementia at the start of the study. They had an average age of 75. Researchers determined if participants took acid reflux drugs by reviewing their medications during study visits and during yearly phone calls. Of the participants, 1,490 people, or 26%, had taken the drugs. Participants were then divided into four groups based on whether they had taken the drugs and for how long, as follows: people who did not take the drugs; those who took the drugs for up to 2.8 years; those who took them for 2.8 to 4.4 years; and people who took them for more than 4.4 years. Participants were then followed for a median duration of 5.5 years. During this time, 585 people, or 10%, developed dementia. Of the 4,222 people who did not take the drugs, 415 people developed dementia, or 19 cases per 1,000 person-years. Person-years represent both the number of people in the study and the amount of time each person spends in the study. Of the 497 people who took the drugs for more than 4.4 years, 58 people developed dementia, or 24 cases per 1,000 person years. After adjusting for factors such as age, sex and race, as well as health-related factors such as high blood pressure and diabetes, researchers found people who had been taking acid reflux drugs for more than 4.4 years had a 33% higher risk of developing dementia than people who never took the drugs. Researchers did not find a higher risk of dementia for people who took the drugs for fewer than 4.4 years. 鈥淢ore research is needed to confirm our findings and explore reasons for the possible link between long-term proton pump inhibitor use and a higher risk of dementia,鈥 said Lakshminarayan. 鈥淲hile there are various ways to treat acid reflux, such as taking antacids, maintaining a healthy weight, and avoiding late meals and certain foods, different approaches may not work for everyone. It is important that people taking these medications speak with their doctor before making any changes, to discuss the best treatment for them, and because stopping these drugs abruptly may result in worse symptoms.鈥 A limitation of the study was that participants were asked once a year about medication use, so researchers estimated use between annual check-ins. If participants stopped and restarted acid reflux drugs in between check-ins, estimation of their use may have been inaccurate. The authors were also unable to assess if participants took over the counter acid reflux drugs. The study was supported by the National Institutes of Health, including the National Heart, Lung, and Blood Institute. Learn more about dementia at , home of the 好色先生鈥檚 free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life on , and . When posting to social media channels about this research, we encourage you to use the hashtags #Neurology and #AANscience.

Brain & Life logo

GET A DOSE OF BRAIN HEALTH

Dive into a wealth of information by visiting Brain & Life庐, where you can explore the freshest updates, tips, and neurologist expert perspectives on brain disease and preventive brain health.


The 好色先生 is the leading voice in brain health. As the world鈥檚 largest association of neurologists and neuroscience professionals with more than 40,000 members, the AAN provides access to the latest news, science and research affecting neurology for patients, caregivers, physicians and professionals alike. The AAN鈥檚 mission is to enhance member career fulfillment and promote brain health for all. A neurologist is a doctor who specializes in the diagnosis, care and treatment of brain, spinal cord and nervous system diseases such as Alzheimer's disease, stroke, concussion, epilepsy, Parkinson's disease, multiple sclerosis, headache and migraine.

Explore the latest in neurological disease and brain health, from the minds at the AAN at or find us on , , , and .

For More Information*

Email media@aan.com

*While content of the 好色先生 (AAN) press releases is developed by the AAN along with research authors and Neurology® editors, we are unable to provide medical advice to individuals. Please contact your health care provider for questions specific to your individual health history or care. For more resources, visit the AAN's patient and caregiver magazine website, .